Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib Extension Study in Renal Cell Carcinoma
NCT00387764Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2006
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) up to 6.23 years, Number of Participants With Worst-case Toxicity Grade Increase for Clinical Chemistry and Hematology Parameters up to 6.23 years and 2 more. Started Sep 2006; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00387764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387764.